Gliolan aminolevulinic acid regulatory update

Australia's Therapeutics Goods Administration ( TGA) approved Gliolan 5-aminolevulinic acid from Specialised Therapeutics Australia as an imaging agent to visualize malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (GBM) on preoperative imaging and who are intended for resection of the tumor. Gliolan was previously available on the Australian government's special access scheme. The product has Orphan Drug status in Australia for the indication. ...